Skip to main content
Martin Tolar, MD, Neurology, New Haven, CT

MartinTolarMD

Neurology New Haven, CT

Physician

Are you Dr. Tolar?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 13 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    800 Howard Ave
    # YPB-3
    New Haven, CT 06519
    Phone+1 203-785-4085

Summary

  • Dr. Martin Tolar, MD is a neurologist in New Haven, Connecticut. He is currently licensed to practice medicine in Connecticut and Massachusetts.

Education & Training

  • Boston University Medical Center
    Boston University Medical CenterResidency, Neurology, 1998 - 2001
  • Charles University in Prague Faculty of Medicine
    Charles University in Prague Faculty of MedicineClass of 1991

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1999 - 2026
  • CT State Medical License
    CT State Medical License 2002 - 2007

Publications & Presentations

PubMed

Press Mentions

  • Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease Conference
    Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease ConferenceNovember 22nd, 2022
  • Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
    Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s DiseaseSeptember 20th, 2022
  • Alzheon Appoints Glenn Pauly as Head of Commercial
    Alzheon Appoints Glenn Pauly as Head of CommercialSeptember 20th, 2022
  • Join now to see all